Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease. The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...
Primary liver cancer incidence increased by 75% between 1990 and 2015, and the disease remains one of the leading causes of cancer death in the world, according to a report from the Global Burden of Diseases Study 2015. Further, hepatitis B virus was the leading cause of new cases of liver cancer in 2015, the research showed. The highest rates of liver cancer incidence, disability-adjusted life-years and mortality occurred in East Asia. Japan had 75% o
Of patients with hepatocellular carcinoma (HCC) and hepatitis C virus, about 75% can achieve virologic cure with direct-acting antiviral (DAA) drugs. In addition, more than 90% of HCC patients who have had a liver transplant can be cured of their HCV infection, according to a new study. Treatment of HCV in patients with HCC was uncommon before the advent of DAA medications. Moreover, the real-world effectiveness of DAA use in this population has remaine...
The effect of sorafenib on overall survival may depend on the hepatitis status of patients with advanced hepatocellular carcinoma (HCC), according to a study published in the Journal of Clinical Oncology. Findings from the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial led to sorafenib becoming the standard of care for patients with advanced unresectable HCC. Patients who were both hepatitis B virus (HBV) negative and h
Initial results from Phase III trial RESORCE to be presented as Late-Breaking Abstract in oral abstract session at WCGC / Median overall survival was 10.6 months for patients treated with regorafenib plus best supportive care versus 7.8 months in the group treated with placebo plus best supportive care. BERLIN, Germany I June 28, 2016 I Bayer today announced results from the Phase III RESORCE trial investigating its oncology compound regorafenib in patien
Liver Cancer rates and deaths are rising all over the world; much of this increase is due to hepatitis C. Three of us from HepCBC attended a Liver Cancer (hepatocellular carcinoma or HCC) conference on Feb. 11th in Toronto, sponsored by the Canadian Assn. for the Study of the Liver (CASL). There will be an article summarizing the most interesting findings in the hepc.bull newsletter soon. Meanwhile, here is a link to the Powerpoint slides:http://www.hepato
The December, 2012 issue of the journal Liver Transplantation discusses the rapidly-increasing demand for liver transplant among HCV+ Americans born between 1941 and 1960. 4% of this birth cohort is HCV+, compared to 1% for the US population as a whole. As this HCV+ population ages, the dangers of advanced cirrhosis and hepatocellular carcinoma (HCC) increase dramatically. 41% of those on the liver transplant list are HCV+, and of these the number who also